中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1551-1560

Expert consensus on clinical application of camrelizumab combined with apatinib in the treatment of hepatocellular carcinoma

DOI: 10.12449/JCH260710
  • Received Date: 2026-06-17
  • Accepted Date: 2026-06-27
  • Published Date: 2026-07-25
    Abstract
  • Camrelizumab combined with apatinib has been approved by the National Medical Products Administration （NMPA） as a first-line therapeutic regimen for hepatocellular carcinoma （HCC）， and a wealth of clinical research evidence and practical experience associated with liver cancer has been accumulated to date. To guide the rational and effective clinical administration of camrelizumab combined with apatinib for HCC treatment， Expert Committee for Liver Cancer and Expert Committee on Safety Management of Anti-Tumor Drugs， Chinese Society of Clinical Oncology， jointly organized multidisciplinary experts and scholars specializing in liver cancer and related disciplines nationwide. This expert consensus has been formulated after thorough discussions and repeated revisions， in order to provide standardized and evidence-based clinical guidance for clinicians.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    Llovet J M, Kelley R K, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572-020-00240-3.
    [2]
    Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
    [3]
    Zheng Rongshou, Chen Ru, Han Bingfeng, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.

    郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
    [4]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [5]
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.. Investigator’s Brochure of Camrelizumab for Injection(Version 9.0)[Z]. Lianyungang: Jiangsu Hengrui Pharmaceuticals Co., Ltd..

    江苏恒瑞医药股份有限公司. 注射用卡瑞利珠单抗研究者手册(第9.0版)[Z]. 连云港: 江苏恒瑞医药股份有限公司.
    [6]
    Center for Drug Evaluation. Camrelizumab for Injection Package Insert[EB/OL].( 2024-03-13). https://www.nmpa.gov.cn/datasearch/#category=yp. https://www.nmpa.gov.cn/datasearch/#category=yp

    国家药品监督管理局药品审评中心. 注射用卡瑞利珠单抗说明书[EB/OL].( 2024-03-13). https://www.nmpa.gov.cn/datasearch/#category=yp. https://www.nmpa.gov.cn/datasearch/#category=yp
    [7]
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.. Investigator’s Brochure of Apatinib Mesylate Tablets(Version 8.0)[Z]. Lianyungang: Jiangsu Hengrui Pharmaceuticals Co., Ltd..

    江苏恒瑞医药股份有限公司. 甲磺酸阿帕替尼片研究者手册(第8.0版)[Z]. 连云港: 江苏恒瑞医药股份有限公司.
    [8]
    Center for Drug Evaluation. Apatinib Mesylate Tablets Package Insert[EB/OL].( 2024-10-17). https://www.nmpa.gov.cn/datasearch/#category=yp. https://www.nmpa.gov.cn/datasearch/#category=yp

    国家药品监督管理局药品审评中心. 甲磺酸阿帕替尼片说明书[EB/OL].( 2024-10-17). https://www.nmpa.gov.cn/datasearch/#category=yp. https://www.nmpa.gov.cn/datasearch/#category=yp
    [9]
    Zhao S, Ren S X, Jiang T, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer[J]. Cancer Immunol Res, 2019, 7( 4): 630- 643. DOI: 10.1158/2326-6066.CIR-17-0640.
    [10]
    Xu J M, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25( 2): 515- 523. DOI: 10.1158/1078-0432.CCR-18-2484.
    [11]
    Mei K M, Qin S K, Chen Z D, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: Cohort A report in a multicenter phase Ib/II trial[J]. J Immunother Cancer, 2021, 9( 3): e002191. DOI: 10.1136/jitc-2020-002191.
    [12]
    Xu J M, Shen J, Gu S Z, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma(RESCUE): A nonrandomized, open-label, phase II trial[J]. Clin Cancer Res, 2021, 27( 4): 1003- 1011. DOI: 10.1158/1078-0432.CCR-20-2571.
    [13]
    Zhang Y, Xu J M, Shen J, et al. Update on overall survival(OS) of RESCUE: An open-label, phase 2 trial of camrelizumab(C) in combination with apatinib(A) in patients with advanced hepatocellular carcinoma(HCC)[J]. J Clin Oncol, 2021, 39( 15_suppl): 4076. DOI: 10.1200/jco.2021.39.15_suppl.4076.
    [14]
    Qin S K, Chan S L, Gu S Z, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310): A randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402( 10408): 1133- 1146. DOI: 10.1016/S0140-6736(23)00961-3.
    [15]
    Qin S K, Gu S Z, Chan S L, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310): Final analysis of a randomised, open-label, international, phase 3 study[J]. Lancet Oncol, 2025, 26( 12): 1598- 1611. DOI: 10.1016/S1470-2045(25)00543-1.
    [16]
    Shroff R T, Shi W, Wu X Z, et al. Clinical outcomes of camrelizumab + rivoceranib vs sorafenib(CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma(uHCC) of non-viral and viral etiology[J]. J Clin Oncol, 2025, 43( 4_suppl): 578. DOI: 10.1200/jco.2025.43.4_suppl.578.
    [17]
    Vogel A, Cheng A L, Shi W, et al. Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma(uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310[J]. J Clin Oncol, 2024, 42( 3_suppl): 509. DOI: 10.1200/jco.2024.42.3_suppl.509.
    [18]
    Chan S L, Kaseb A O, Shi W, et al. Patient-reported outcomes(PROs)<65 or ≥ 65 years old(yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma(uHCC)[J]. J Clin Oncol, 2024, 42( 3_suppl): 456. DOI: 10.1200/jco.2024.42.3_suppl.456.
    [19]
    Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018.
    [20]
    Cappuyns S, Corbett V, Yarchoan M, et al. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: A review[J]. JAMA Oncol, 2024, 10( 3): 395- 404. DOI: 10.1001/jamaoncol.2023.2677.
    [21]
    Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese society of clinical oncology(CSCO) guidelines for clinical application of immunocheckpoint inhibitors 2025[M]. Beijing: People’s Medical Publishing House, 2025.

    中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂临床应用指南2025[M]. 北京: 人民卫生出版社, 2025.
    [22]
    Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy[J]. Lancet Oncol, 2020, 21( 10): e463- e476. DOI: 10.1016/S1470-2045(20)30328-4.
    [23]
    Llovet J M, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19( 3): 151- 172. DOI: 10.1038/s41571-021-00573-2.
    [24]
    Jin Z C, Zhong B Y, Chen J J, et al. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC(CHANCE2211): A propensity score matching study[J]. Eur Radiol, 2023, 33( 12): 8669- 8681. DOI: 10.1007/s00330-023-09754-2.
    [25]
    Zhu H D, Fan W J, Zhao C, et al. Transarterial chemoembolization combined with camrelizumab and rivoceranib for unresectable hepatocellular carcinoma(CHANCE2005/CARES-005): A randomized phase II trial[J]. J Clin Oncol, 2026, 44( 11): 959- 969. DOI: 10.1200/JCO-25-01796.
    [26]
    Zhang T Q, Geng Z J, Zuo M X, et al. Camrelizumab(a PD-1 inhibitor) plus apatinib(an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C(TRIPLET): A phase II study[J]. Sig Transduct Target Ther, 2023, 8: 413. DOI: 10.1038/s41392-023-01663-6.
    [27]
    Li J X, Su T S, Gong W F, et al. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: A single-arm trial[J]. Hepatol Int, 2022, 16( 5): 1179- 1187. DOI: 10.1007/s12072-022-10396-7.
    [28]
    Hu Y, Zhou M, Tang J, et al. Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus[J]. Clin Cancer Res, 2023, 29( 20): 4088- 4097. DOI: 10.1158/1078-0432.CCR-22-2592.
    [29]
    Xu B, Zhu X D, Shen Y H, et al. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody[J]. Front Immunol, 2022, 13: 1016736. DOI: 10.3389/fimmu.2022.1016736.
    [30]
    Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer, China Anti-Cancer Association. Chinese expert consensus on conversion and perioperative therapy of primary liver cancer(2024 edition)[J]. Chin J Dig Surg, 2024, 23( 4): 492- 513. DOI: 10.3760/cma.j.cn115610-20240228-00135.

    中国抗癌协会肝癌专业委员会转化治疗协作组. 原发性肝癌转化及围手术期治疗中国专家共识(2024版)[J]. 中华消化外科杂志, 2024, 23( 4): 492- 513. DOI: 10.3760/cma.j.cn115610-20240228-00135.
    [31]
    Zeng Z, Huang H, Zhu G, et al. Sequential hepatectomy for hepatocellular carcinoma with inadequate future-liver-remnant after portal vein ligation in combination with apatinib plus camrelizumab(PLACES): a single-arm prospective pilot study[J]. Hepatobiliary Surg Nutr, 2026, 15( 1): 6. DOI: 10.21037/hbsn-24-363.
    [32]
    Zhao L, Zhang B, Shi XT, et al. Camrelizumab combined with apatinib and hepatic artery infusion chemotherapy as conversion therapy for patients with unresectable hepatocellular carcinoma: A single-arm exploratory clinical study[J]. Cancer Res, 2024, 84( 6_Suppl): 2395.
    [33]
    Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial[J]. J Immunother Cancer, 2022, 10( 4): e004656. DOI: 10.1136/jitc-2022-004656.
    [34]
    Bai X, Chen Y, Zhang X, et al. CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma[J]. Ann Oncol, 2022, 33: S868. DOI: 10.1016/j.annonc.2022.07.836.
    [35]
    Wang Z, Fan J, Zhou S L, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence(CARES-009): A randomised phase 2/3 trial[J]. Lancet, 2025, 406( 10515): 2089- 2099. DOI: 10.1016/S0140-6736(25)01720-9.
    [36]
    Shi Guoming, Huang Xiaoyong, Ren Zhenggang, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors(2021 edition)[J]. Chin J Dig Surg, 2021, 20( 12): 1241- 1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.

    施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20( 12): 1241- 1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
    [37]
    Maitland M L, Bakris G L, Black H R, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors[J]. J Natl Cancer Inst, 2010, 102( 9): 596- 604. DOI: 10.1093/jnci/djq091.
    [38]
    Committee for Revision of the Chinese Guidelines for the Prevention and Treatment of Hypertension, Chinese Hypertension League, Hypertension Branch of China International Exchange and Promotive Association for Medical and Health Care, et al. Guidelines for prevention and treatment of hypertension in China(revised in 2024)[J]. Chin J Hypertens, 2024, 32( 7): 603- 700. DOI: 10.16439/j.issn.1673-7245.2024.07.002.

    中国高血压防治指南修订委员会, 高血压联盟, 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32( 7): 603- 700. DOI: 10.16439/j.issn.1673-7245.2024.07.002.
    [39]
    Expert Committee on Safety Management of Antineoplastic Drugs, Chinese Society of Clinical Oncology, Expert Committee on Immunotherapy, Chinese Society of Clinical Oncology. Chinese expert consensus on the clinical diagnosis and treatment of reactive cutaneous capillary endothelial proliferation induced by camrelizumab[J]. Chin Clin Oncol, 2020, 25( 9): 840- 848. DOI: 10.3969/j.issn.1009-0460.2020.09.012.

    中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 中国临床肿瘤学会免疫治疗专家委员会. 卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识[J]. 临床肿瘤学杂志, 2020, 25( 9): 840- 848. DOI: 10.3969/j.issn.1009-0460.2020.09.012.
    [40]
    Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese society of clinical oncology(CSCO) immunocheckpoint inhibitor-related toxicity management guidelines 2025[M]. Beijing: People’s Medical Publishing House, 2025.

    中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2025[M]. 北京: 人民卫生出版社, 2025.
    [41]
    Wang F, Qin S K, Sun X C, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: Data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13( 1): 47. DOI: 10.1186/s13045-020-00886-2.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (97) PDF downloads(28) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return